#United States #Foster City #Trodelvy #Gilead Sciences #Biktarvy

Gilead Reports Strong Q1 Performance for 2026

Gilead Sciences has recently revealed its performance for the first quarter of 2026, showcasing a robust growth trajectory fueled by significant increases in product sales. Excluding the sales of remdesivir (Veklury), Gilead's product revenue surged to $6.8 billion, marking an impressive 8% increase compared to the same quarter last year. The company's CEO, Daniel O'Day, attributed this success to the strong demand for various HIV treatments and the successful performance of their remedies, including Trodelvy (sacituzumab govitecan) and Livdelzi (seladelpar).

Financial Highlights for Q1 2026

Gilead's total revenue for the first quarter of 2026 was pegged at $7 billion, which represents a 4% rise from the same period in 2025, driven primarily by growth in HIV products. The earnings per share (EPS) saw a significant boost to $1.61, compared to $1.04 in the prior year, reflecting improved product sales and a decrease in R&D expenses related to acquisitions.

Product Sales Breakdown

In the first quarter of 2026, the company's product revenue reached $6.9 billion, a 5% increase from Q1 2025. Stripping out Veklury, sales stood at $6.8 billion, showing substantial demand especially for Gilead's HIV product line. The sales performance of these products was mainly buoyed by higher demand and a rise in average selling prices.

• - HIV Products: Recorded $5 billion in sales, reflecting a 10% increase year-on-year, attributed to escalating demand despite slight inventory impacts.
• - Biktarvy: Generated $3.4 billion in revenue, a 7% increase, driven largely by increased demand.
• - Descovy: Also showed remarkable growth of 38%, with sales of $807 million.

Despite these gains, sales of Veklury fell to $144 million, a staggering 52% decrease from the previous year due to reduced COVID-19 hospitalizations.

Comprehensive Growth and Future Guidance

O'Day highlighted that Gilead is poised for continued growth, especially in the oncology and inflammatory disease fields, thanks to a robust pipeline bolstered by recent acquisitions of Arcellx, Ouro Medicines, and Tubulis. He anticipates the launch of up to four new products by 2026 and updates on five phase III trials, reinforcing Gilead's commitment to sustained growth.

As part of their 2026 guidance, Gilead has adjusted its product sales forecast upwards, with anticipated total product revenue ranging from $30 billion to $30.4 billion. The revision also includes a slight decrease in projected diluted EPS, now forecasted between -$3.25 and -$2.85 driven by anticipated acquisition-related costs.

Investment in HIV Prevention and Innovative Drug Development

Gilead continues to make significant investments in HIV prevention and research, including a recent announcement of a $12 million commitment to expand HIV prevention initiatives across 14 states and Washington D.C.

In addition, the company is focusing on innovative drug development with the progression of new treatments approved by regulatory authorities, including a combination therapy for HIV that is set for priority review by the FDA.

Concluding Remarks

Gilead Sciences remains dedicated to creating a healthier world. With a strong emphasis on innovative treatments for life-threatening diseases such as HIV, hepatitis, COVID-19, and cancer, Gilead's advancements in the biotechnology sector continue to make strides in improving patient outcomes globally. As the company prepares for future growth, stakeholders can look forward to exciting developments in both product offerings and strategic initiatives.